

## ASX ANNOUNCEMENT

ASX:RSH OTCQB:RSHUF

28<sup>th</sup> November 2022**wheezo<sup>®</sup> REMOTE PATIENT MONITORING (RPM) SELECTED BY LEADING USA HEART CENTER TO IMPROVE MANAGEMENT OF COPD IN HEART PATIENTS.****Highlights:**

- Arkansas Heart Hospital (AHH), a world class leading cardiac centre of excellence hospital, selects wheezo<sup>®</sup> and Access Telehealth's cloud-based RPM solution, Remotli, to help improve health outcomes and reduce hospital re-admissions costs
- the wheezo<sup>®</sup> RPM program selected as part of a **standard of care** for CVD patients also suffering from Chronic Obstructive Pulmonary Disease (COPD).
- Remote Patient Monitoring (RPM) will be delivered by Access Telehealth using wheezo with their full-service premium model that includes software, patient engagement and education. device logistics, and clinical monitoring. Patient selection and recruitment for the full program will commence immediately.

**Respiri Limited (ASX:RSH) ("Respiri" or the "Company")**, an eHealth SaaS Company supporting respiratory health management is pleased to announce that Arkansas Heart Hospital (AHH) has chosen the wheezo<sup>®</sup> RPM program as an addition to the standard of care to help better manage CVD patients that also have Chronic Obstructive Pulmonary Disease (COPD), a common co-morbidity that further complicates the management of these very high-risk patients.

The program was secured with our RPM partner Access Telehealth and will provide a full RPM solution that includes the Remotli platform, patient engagement and remote monitoring. The program is not a pilot and commences immediately and is recognised by AHH as an important addition to patient management to reduce avoidable hospital re-admissions that place a huge healthcare resource and economic burden on medical institutions. 39%<sup>1</sup> of patients with Cardiovascular Disease (CVD) also have Chronic Obstructive Pulmonary Disease (COPD) which further complicates management and is a key contributor to hospital re-admissions.

RPM Current Procedural Terminology (CPT) reimbursement codes from this program will be processed through Centers for Medicare and Medicaid Services (CMS) and private insurers.

Arkansas Heart Hospital was founded in 1997 by a group of patient-centric cardiologists led by Dr. Bruce Murphy to provide world class patient care in an institution that would serve people throughout Arkansas. AHH is a 112-bed facility staffed with 9 cardiologists and other specialties physicians, employing some 875 staff and with a respiratory/sleep laboratory. With an extensive referral network, AHH is one of the largest private cardiovascular healthcare organisations in the USA, servicing thousands of patients in southern USA, providing almost 22,000 annual patient days of care equating to almost USD\$648M in annual patient care billings.

1. Defining the relationship between COPD and CVD: what are the implications for clinical practice? [Ther Adv Respir Dis](#). 2018 Jan-Dec; 12

**ASX ANNOUNCEMENT**

ASX:RSH OTCQB:RSHUF

AHH holds a 5 Star, Center for Medicare & Medicaid Services (CMS) rating and is one of the country's largest private providers of CVD care. CMS rates more than 4,500 hospitals throughout the United States and AHH has received the 5-Star rating, the highest accolade, and is also the only hospital in Arkansas recognized for its commitment to outstanding patient care for two years in a row.

This is the first time that AHH will provide such a program focused on remote respiratory disease monitoring using the novel wheezo<sup>®</sup> device to track and monitor patient physiologic data on hospital discharge and between clinical visits to help improve the health of patients and reduce expensive, resource draining and often avoidable hospital re-admissions

Marjan Mikel, CEO of Respiri said, "Patients with cardiovascular disease are difficult to manage and often have numerous co-morbidities that further complicate their treatment. COPD is one such common complication and we are delighted that the Arkansas Heart, a preeminent cardiovascular organization, has chosen to add the wheezo<sup>®</sup> RPM program to the standard of care for the thousands of CVD patients with COPD under their care to improve health outcomes and reduce hospital re-admissions."

"Like Minnesota Lung Centre, this agreement was finalised relatively quickly. US Healthcare organisations understand the importance of preventative healthcare and they remain very positive about what wheezo<sup>®</sup> and RPM can provide".

Nicholas Smedley, Executive Chairman of Respiri said, "It is fantastic to see the wheezo<sup>®</sup> sales cycle continuing to be reduced. Securing Arkansas Heart in record time and moving straight to patient selection and recruitment is a testament to our partners and the hard work of the Respiri team."

Myra Ameigh, CEO Access Telehealth said Remote Patient Monitoring offers patient's living with cardiovascular disease clinical support and a better understanding of how to manage their condition prior to and post procedure. This leads to reduced cost for both patients and the hospital related to emergency care and readmissions. Access Telehealth is excited to be working with the impressive team at AAH".

Respiri together with RPM partners are in advanced discussions with a number of other potential wheezo<sup>®</sup> RPM customers who also see the benefits of introducing RPM services as part of patient standard of care.

**For further information, investors and media please contact:**

**Mr Marjan Mikel**  
CEO & Managing Director  
Respiri Limited  
P: +61 408 462 873  
E: [marjan@respiri.co](mailto:marjan@respiri.co)

**Mr Nicholas Smedley**  
Executive Chairman  
Respiri Limited  
P: +61 447 074 160  
E: [nicholas@respiri.co](mailto:nicholas@respiri.co)

wheezo<sup>®</sup> is a registered trademark of Respiri Limited.

## ASX ANNOUNCEMENT

ASX:RSH OTCQB:RSHUF

---

### About Respiri Limited

Respiri Limited (ASX:RSH, OTCQB:RSHUF) is an international e-Health SaaS company supporting respiratory health management focusing primarily on supporting the US remote patient monitoring market. Its world-first technology detects wheeze, a typical symptom of Asthma, COPD and respiratory disease to provide an objective measure of airway limitation. Respiri created technology optimises how patients in partnership with their physicians manage chronic respiratory conditions. These solutions can help transform the way physicians interact with respiratory patients while they are away from the clinic. wheezo®, is an FDA cleared Class II Medical Device, the respiri™ app (patient-user-interface) and the secure health portal can help different health organisations and providers connect with patients to improve collaboration and help improve respiratory condition management. In the USA, wheezo® can be integrated into Remote Patient Monitoring (RPM) programs and qualifies for RPM Current Procedural Terminology (CPT) reimbursement.

Respiri's mission is to help improve quality of life for hundreds of millions of children and adults around the world with respiratory disorders and dramatically reduce hospital admissions and the economic burden of Asthma and COPD. Respiri Limited's operations are based in Melbourne, Australia with offices in New York City, USA.

For additional information about Respiri Limited please visit our corporate website [www.respiri.co/au](http://www.respiri.co/au)

---

### About wheezo®

Developed in Australia, with the support of an international panel leading respiratory specialists and other healthcare professionals, the innovative wheezo® device analyses breath sounds for wheeze, and the intuitive mobile application engages patients to log symptoms and triggers to build a personal profile to share data with healthcare providers so patients and physicians can have more informed discussions in relation to symptoms. The platform has been designed to extend care beyond the clinic which may lead to better health outcomes and improved quality of life for patients.

For information about our product offering in the US including wheezo® please visit [www.respiri.co/us](http://www.respiri.co/us)

wheezo® is a registered trademark of Respiri Limited.

### About Access Telehealth

Access Telehealth is a digital health company dedicated to delivering innovative connected care solutions for management of people living with chronic disease. The Remotli platform uniquely simplifies remote care delivery with patient engagement and productivity driven dashboard tools to support effective patient care and compliance. Automated care-time tracking, and reimbursement reports makes it easy to boost revenue to support vital chronic disease management programs including Remote Physiologic Monitoring, Remote Therapeutic Monitoring, Transitional Care, Chronic Care Management, Telemedicine and more. Focusing on Remote Physiologic Monitoring and virtual care initiatives, the Access Telehealth clinical team delivers patient-centric remote monitoring services to support disease specific chronic care programs for health systems, payors, and providers, to enhance care delivery. [www.accessrpm.com/](http://www.accessrpm.com/)

### Forward Looking Statements

Certain statements made in this announcement are forward-looking statements. These forward-looking statements are not historical facts but are based on Respiri current expectations, estimates and projections about the industry in which Respiri operates, and its beliefs and assumptions. Words such as "anticipates," "expects," "intends," "plans," "believes," "seeks," "estimates," "guidance" and similar expressions are intended to identify forward looking statements and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties, particularly those risks or uncertainties inherent in the process of developing technology and in the endeavour of building a business around such products and services. These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and other factors, some of which are beyond the control of Respiri, are difficult to predict and could cause actual results to differ materially from those expressed or forecasted in the forward-looking statements. Respiri cautions shareholders and prospective shareholders not to place undue reliance on these forward-looking statements, which reflect the view of Respiri only as of the date of this release. The forward-looking statements made in this announcement relate only to events as of the date on which the statements are made. Respiri will not undertake any obligation to release publicly any revisions or updates to these forward-looking statements to reflect events, circumstances or unanticipated events occurring after the date of this announcement except as required by law or by any appropriate regulatory authority.